Armata Pharmaceuticals Inc (ARMP)

Armata Pharmaceuticals Stock Analysis & Ratings

ARMP Stock Chart & Stats

Day’s Range$4.26 - $4.63
52-Week Range$2.82 - $6.49
Previous Close$4.2
Average Volume (3M)14.41K
Market Cap$167.20M
P/E Ratio-4.8
Next EarningsAug 11, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score3
EPS (TTM)-0.97



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Armata Pharmaceuticals’s price range in the past 12 months?
Armata Pharmaceuticals lowest stock price was $2.82 and its highest was $6.49 in the past 12 months.
    What is Armata Pharmaceuticals’s market cap?
    Armata Pharmaceuticals’s market cap is $167.20M.
      What is Armata Pharmaceuticals’s price target?
      The average price target for Armata Pharmaceuticals is $8.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $9.00 ,the lowest forecast is $7.00. The average price target represents 72.79% Increase from the current price of $4.63.
        What do analysts say about Armata Pharmaceuticals?
        Armata Pharmaceuticals’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
          When is Armata Pharmaceuticals’s upcoming earnings report date?
          Armata Pharmaceuticals’s upcoming earnings report date is Aug 11, 2022 which is in 85 days.
            How were Armata Pharmaceuticals’s earnings last quarter?
            Armata Pharmaceuticals released its earnings results on May 12, 2022. The company reported -$0.3 earnings per share for the quarter, missing the consensus estimate of -$0.165 by -$0.135.
              Is Armata Pharmaceuticals overvalued?
              According to Wall Street analysts Armata Pharmaceuticals’s price is currently Undervalued.
                Does Armata Pharmaceuticals pay dividends?
                Armata Pharmaceuticals does not currently pay dividends.
                What is Armata Pharmaceuticals’s EPS estimate?
                Armata Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Armata Pharmaceuticals have?
                Armata Pharmaceuticals has 36,110,000 shares outstanding.
                  What happened to Armata Pharmaceuticals’s price movement after its last earnings report?
                  Armata Pharmaceuticals reported an EPS of -$0.3 in its last earnings report, missing expectations of -$0.165. Following the earnings report the stock price went up 3.684%.
                    Which hedge fund is a major shareholder of Armata Pharmaceuticals?
                    Currently, no hedge funds are holding shares in ARMP


                    Armata Pharmaceuticals Stock Analysis

                    Smart Score
                    Price Target
                    ▲(72.79% Upside)
                    Moderate Buy
                    The Armata Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                    Learn more about TipRanks Smart Score

                    Company Description

                    Armata Pharmaceuticals Inc

                    Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains. The company was founded on May 9, 2019 and is headquartered in Los Angeles, CA.

                    Similar Stocks
                    Price & Change
                    CASI Pharmaceuticals

                    Popular Stocks

                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis